FDA Approves Eli Lilly’s Alzheimer’s Drug, Posing New Competition for Eisai’s Leqembi
Eli Lilly has successfully obtained FDA approval for its Alzheimer’s disease medication, Kisunla, a drug with similar therapeutic mechanisms to Eisai’s Alzheimer’s treatment but offers distinct dosing benefits that may attract patient preference. This approval follows unanimous support from an FDA advisory committee, recognizing Kisunla’s capability in decelerating cognitive decline outweighs its associated safety risks. […]